Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer
Titel:
Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer
Auteur:
Roubaud, Guilhem Attard, Gerhardt Boegemann, Martin Olmos, David Trevisan, Marco Antoni, Laurent Pascoe, Katie Capone, Camille Van Sanden, Suzy Hashim, Mahmoud Palmer, Stephen Chi, Kim